- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07716020
XPAD European Feasibility Study
Prospective, Non-randomized, European Feasibility Clinical Study to Assess the Safety and Performance of the Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Sandra Kohler
- Número de telefone: +31 (0) 6 55 55 57 14
- E-mail: sandra.kohler@xeltis.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Participants with peripheral artery occlusion who require elective lower-limb bypass surgery
- Participant has Rutherford grade 3 or 4 occlusive vascular disease and TASC C or D lesions.
- At least 18 years of age at screening
- Suitable anatomy while avoiding joints (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline)
- Participant has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
- Participant has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography
- Life expectancy of at least 24 months
Exclusion Criteria:
- Participant requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure.
- Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above)
- History of acute arterial occlusion requiring an emergent intervention within the last 12 months
- Severe chronic renal insufficiency (serum creatinine >2.5 mg/dL) or undergoing hemodialysis
- Previous renal transplant
- Uncontrolled arterial hypertension (BP >200 mmHg) at 2 successive readings
- Uncontrolled or poorly controlled diabetes
- Abnormal blood values that could influence participant recovery and or/ graft hemostasis
- Reduced liver function, defined as: >2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) >1.5 or prothrombin time (PT) >18 seconds
- Any active local or systemic infection
- Known heparin- induced thrombocytopenia, active bleeding disorder and/or any coagulopathy or thromboembolic disease
- Allergies to study device (nitinol) or agents/medication, such as contrast agents, aspirin or NOACs, that can't be controlled medically
- Previous enrolment in this study
- Participant is participating in another study
- Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
- Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit
Intra-operative exclusion criteria:
1. Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: XPAD
|
The XPAD bypass conduit is a sterile, restorative biodegradable polymer-based vascular conduit, consisting of a tubular structure with a 33cm length and 6mm inner diameter.
It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System).
The XPAD conduit is in a straight configuration and may be implanted in the lower limb for elective bypass surgery.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Primary patency rate
Prazo: 12 months post-implant
|
Primary patency defined as the interval between conduit implantation and the first intervention to maintain or restore patency
|
12 months post-implant
|
|
Freedom from device-related SAE
Prazo: Day 1, 30 days, 6 months, and 12 months post-implant
|
Day 1, 30 days, 6 months, and 12 months post-implant
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Implantation success rate
Prazo: Day 1
|
Implantation success defined as a technically successful XPAD conduit implantation in the planned configuration, free from kinking and tension in the anastomoses, and a patent XPAD conduit at the moment of discharge.
|
Day 1
|
|
Freedom from Major Bleeding events
Prazo: Day 1, 30 days and 6 months post-implant
|
Major Bleeding defined as type 3, 4 or 5 bleeding according to the Bleeding Academic Research Consortium (BARC) classifications
|
Day 1, 30 days and 6 months post-implant
|
|
Patency (primary, primary assisted, and secondary) rates
Prazo: 6, 12, 24, 36, 48 and 60 months post-implant
|
Primary patency defined as the interval between conduit implantation and the first intervention to maintain or restore patency. Assisted primary patency defined as the interval between conduit implantation and the first occlusion (thrombosis), including interventions (operative or endovascular) aimed to maintain the functionality the conduit. Secondary patency defined as the interval between conduit implantation and abandonment with or without interventions (operative or endovascular) aimed to maintain the functionality the conduit, including occurrence of a censored event (death, change of modality, loss of follow-up). |
6, 12, 24, 36, 48 and 60 months post-implant
|
|
Freedom from device-related SAE
Prazo: 24, 36, 48 and 60 months post-implant
|
24, 36, 48 and 60 months post-implant
|
|
|
Rate of wound/conduit infections
Prazo: 30 days, 6, 12, 24, 36, 48 and 60 months post-implant
|
30 days, 6, 12, 24, 36, 48 and 60 months post-implant
|
|
|
Freedom from Major Amputations
Prazo: 30 days, 6, 12, 24, 36, 48, and 60 months post-implant
|
Major Amputation defined as any amputation that results in limb shortening
|
30 days, 6, 12, 24, 36, 48, and 60 months post-implant
|
|
Freedom from all-cause mortality
Prazo: 30 days, 6, 12, 24, 36, 48, and 60 months post-implant
|
30 days, 6, 12, 24, 36, 48, and 60 months post-implant
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- XEL-CR-17
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .